The Potential Therapeutic Advantages of Using Nanotechnology in the Treatment of Liver Fibrosis: A Review | ||||
| Egyptian Academic Journal of Biological Sciences, B. Zoology | ||||
| Volume 17, Issue 1, June 2025, Page 55-86 PDF (768.14 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/eajbsz.2025.410264 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hanaa M. Ashqar 1; Abdulkader M. Shaikh Omar 2; Salim M. El Hamidy 2
| ||||
| 1Biological Sciences Department, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. | ||||
| 2Princess Dr. Najla Bint Saud Al-Saud Center for Excellence Research in Biotechnology, King Abdulaziz University, Jeddah, Saudi Arabia. | ||||
| Abstract | ||||
| Liver fibrosis is a complex medical condition characterized by the abnormal and excessive buildup of extracellular matrix proteins, primarily collagen, in liver tissue, disrupting normal tissue architecture and functionality. This accumulation can lead to various complications and adversely affect the overall health of the involved organs. This pathological phenomenon typically arises from chronic liver injury, often caused by multiple factors. Early detection and intervention are crucial to minimize ongoing liver damage and enhance clinical outcomes for those affected. While significant progress has been made in understanding the molecular pathways involved in liver fibrosis, there remains a strong demand to expand the treatment options available for this condition. The use of nanoparticles (NPs) in combination therapies has gained popularity, leveraging advancements in drug delivery systems. This approach enables the simultaneous administration of several pharmacological agents, thus enhancing therapeutic effectiveness for liver fibrosis and other conditions. Researchers increasingly view NPs as innovative tools capable of optimizing combination therapies through targeted delivery of medications, thereby improving bioavailability and overall therapeutic impact. Recent research in nanotechnology highlights the potential of NP-mediated drug delivery systems to change the treatment landscape for liver fibrosis. Various NP systems, including both inorganic and organic NPs, present innovative avenues for achieving sustained drug release, targeted treatment, and enhanced stability, reducing the likelihood of rapid clearance in infected tissues. This review examines the evolving role of nanotechnology in managing liver fibrosis, summarizing recent findings and assessing various technologies for their effectiveness and potential. We will showcase innovative strategies and significant results while comparing nanoparticle methods to evaluate their efficacy. Furthermore, we will investigate the applications of nanomaterials in drug delivery, targeting, and diagnostics, unveiling the exciting advancements shaping the future of liver fibrosis treatment. | ||||
| Keywords | ||||
| Liver fibrosis; nanomedicine; inorganic nanoparticles; organic nanoparticles; drug delivery; combination therapy | ||||
|
Statistics Article View: 379 PDF Download: 303 |
||||
